Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: Exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes

Lung

Volumn 191, Issue 5, 2013, Pages 491-499

  Locatelli Sanchez, Myriam ^a,b   Couraud, Sébastien ^a,b   Arpin, Dominique ^c   Riou, Robert ^d   Bringuier, Pierre Paul ^e   Souquet, Pierre Jean ^a,b  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b UNIVERSITÉ LYON 1   (France)

^c CROIX ROUSSE HOSPITAL   (France)

^d CENTRE HOSPITALIER DE VALENCE   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Biomarkers; EGFR; Lung cancer; Metastasis; Tyrosine kinase inhibitors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; EXONS; FEASIBILITY STUDIES; FEMALE; FRANCE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84884812395     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-013-9482-4     Document Type: Article

References (29)

1. Pao W, Miller VA (2005) Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23(11):2556-2568
2. Sharma SV et al (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7(3):169-181
3. He M et al (2012) EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res 18(6):1790-1797
4. Somatic Mutations in Epidermal Growth Factor Receptor Database (2008). www.somaticmutations-egfr.org. Accessed 30 May 2013
5. Dahabreh IJ et al (2010) Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 16(1):291-303
6. Girard N et al (2012) Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J 39(2):366-372
7. Rosell R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239-246
8. Zhou C et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12(8):735-742
9. Mitsudomi T et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121-128
10. Maemondo M et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380-2388
11. Institut National du Cancer (INCA) (2010) Cancer du poumon non à petites cellules. Formes localisées non opérables, localement avancées et métastatiques. Recommandations & référentiels. www.e-cancer.fr. Accessed 30 May 2013
12. Keedy VL et al (2011) American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29(15):2121-2127
13. Andre F et al (2012) Biomarker discovery, development, and implementation in France: a report from the French National Cancer Institute and cooperative groups. Clin Cancer Res 18(6):1555-1560
14. Beau-Faller M et al (2011) Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project - part 1). J Thorac Oncol 6(6):1006-1015
15. Ruppert AM et al (2011) A simple view on lung cancer biology: the EGFR pathway. Rev Mal Respir 28(4):565-577
16. Han JY et al (2012) First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 30(10):1122-1128
17. Fukuoka M et al (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29(21):2866-2874
18. Talaulikar D et al (2008) A comparative study of the quality of DNA obtained from fresh frozen and formalin-fixed decalcified paraffin-embedded bone marrow trephine biopsy specimens using two different methods. J Clin Pathol 61(1):119-123
19. Wickham CL et al (2000) Formic acid decalcification of bone marrow trephines degrades DNA: alternative use of EDTA allows the amplification and sequencing of relatively long PCR products. Mol Pathol 53(6):336
20. Pirker R et al (2010) Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 5(10):1706-1713
21. Institut National du Cancer (INCA) (2012) Molecular genetic testing for equal access to targeted therapies in France in 2011, Reports & Summaries. http://www.e-cancer.fr. Accessed 30 May 2013
22. Rosell R et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361(10):958-967
23. de Mello RA et al (2012) EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study. Tumour Bio 33(6):2061-2068
24. Sahoo R et al (2011) Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer 73(3):316-319
25. Greulich H et al (2005) Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2(11):e313
26. Jiang J et al (2005) Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res 65(19):8968-8974
27. Petrelli F et al (2012) Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. Clin Lung Cancer 13(2):107-114
28. Besse B, Zalcman G (2011) What is the best sequence of treatment for patients with EGFR mutations? Rev Pneumol Clin 67(Suppl 1):S24-S29
29. Nowak F et al (2012) Tumour molecular profiling for deciding therapy - the French initiative. Nat Rev Clin Oncol 9(8):479-486